Harald Paganetti
Harvard University
400 Papers
1.7K Citations
Harald Paganetti is an academic researcher from Harvard University. The author has contributed to research in topics: Proton therapy & Medicine. The author has an hindex of 67, co-authored 367 publications. Previous affiliations of Harald Paganetti include Paul Scherrer Institute & AT&T.
Chat about Author
Papers
SU-F-BRD-15: Quality Correction Factors in Scanned Or Broad Proton Therapy Beams Are Indistinguishable
Jefferson Sorriaux,Marcia A. Testa,Harald Paganetti,D Bertrand,J. Orban de Xivry,John Aldo Lee,Hugo Palmans,Stefaan Vynckier,Edmond Sterpin +8 more
TL;DR: Quality correction factors for ion chamber response in scanned and broad proton therapy beams are identical under reference conditions within the calculation uncertainties, indicating that quality correction factors published in IAEA TRS-398 can be used for scanned beams in the SOBP of a high-energy proton beam.
1
Quantitative assessment of the accuracy of proton beam range verification with PET/CT
Antje Knopf,Katia Parodi,Harald Paganetti,E Cascio,Ali A. Bonab,Thomas Bortfeld +5 more
- 01 Jan 2007
TL;DR: In this article, the authors investigated the sensitivity and accuracy of the PET/CT treatment verification method in the presence of highly inhomogeneous tissue regions as well as of metallic implants.
1
Ep-1587 cell survival responses to modulated proton beams delivered by passive scattering and pencil beam scanning
Conor K. McGarry,Karl T. Butterworth,B Clasie,J. Schumann A Carabe-Fernandez,Nicolas Depauw,Hanne M. Kooy,H.S. Ming,Shikui Tang,Joe M. O'Sullivan,Giuseppe Schettino,Stephen J. McMahon,Harald Paganetti,Kathryn D. Held,Kevin M. Prise,Alan R. Hounsell +14 more
1
TU-C-M100J-05: Image Guided 4D Monte Carlo Study of the Dosimetric Effects of Intra/inter Fraction Motion in Lung Tumors
Joao Seco,S Gianolini,Gregory C. Sharp,Ziji Wu,David P. Gierga,Florian Buettner,Harald Paganetti +6 more
TL;DR: Comparison between IGMC dose distributions for free breathing, inhale and exhale phases, show that dose coverage of the primary/secondary tumors was significant worse in the inhale phase relative to the exhale/free‐breathing phases.
1